Relations of clinical symptoms with dopamine transporter imaging in drug-naïve Parkinson's disease.
Akinetic-Rigid score
Dopamine transporter imaging
Freezing of gait
Overactive bladder symptom score
Parkinson’s disease
Tremor score
Unified Parkinson’s disease rating scale
Journal
Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
02
05
2019
revised:
22
05
2020
accepted:
23
05
2020
pubmed:
28
6
2020
medline:
16
6
2021
entrez:
28
6
2020
Statut:
ppublish
Résumé
The aim of the present study was to determine the relations of clinical symptoms with nigrostriatal neuron loss in drug-naïve patients with Parkinson's disease (PD). We examined the severity of motor symptoms and freezing of gait (FOG), falls and overactive bladder (OAB) in PD patients and their relations with striatal dopamine transporter (DAT) binding. Thirty-two untreated PD patients (14 men and 18 women with a mean age of 71.4 ± 7.2 years) were included in this study. Clinical assessments were performed by using Unified Parkinson's Disease Rating Scale (UPDRS) and overactive bladder symptom score (OABSS), and striatal dopamine transporter (DAT) binding was measured by The results showed that striatal DAT availability was significantly lower in the high UPDRS motor score group, high akinetic-rigid score group, FOG group, and OAB group than in the low UPDRS motor score group, low akinetic-rigid score group, non-FOG group, and non-OAB group. However, the results also showed that there was no significant difference in striatal DAT availability between the high tremor score group and low tremor score group or between the faller group and non-faller group. The severity of bradykinesia and axial symptoms and the existence of FOG and OAB in untreated PD patients are related to a decrease in striatal DAT availability. Severity of tremors and occurrence of falls are not related to a decrease in striatal DAT availability. The mechanisms underlying the clinical symptoms of PD involve not only dopaminergic pathways but also non-dopaminergic pathways.
Identifiants
pubmed: 32593043
pii: S0303-8467(20)30303-6
doi: 10.1016/j.clineuro.2020.105960
pii:
doi:
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105960Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.